

REGENERON PHARMACEUTICALS INC
 Form 4
 February 18, 2016

FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
 Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0287
 Expires: January 31, 2015
 Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *
 Sanofi

2. Issuer Name and Ticker or Trading Symbol
 REGENERON
 PHARMACEUTICALS INC
 [REGN]

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

____ Director
 ____ Officer (give title below)
 ____ 10% Owner
 ____ Other (specify below)

(Last) (First) (Middle)

3. Date of Earliest Transaction
 (Month/Day/Year)
 02/16/2016

54 RUE LA BOETIE
 (Street)

4. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)

Form filed by One Reporting Person
 Form filed by More than One Reporting Person

PARIS, IO 75008

(City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
			Code	V	Amount or Price (A) or (D)			
Common Stock	02/16/2016		P		\$ 2,145 <u>(1) (2)</u> 387.4283 <u>(1) (3)</u>	23,194,653	I	See note (4)
Common Stock	02/16/2016		P		\$ 2,196 <u>(1) (2)</u> 388.2999 <u>(1) (5)</u>	23,196,849	I	See note (4)
Common Stock	02/16/2016		P		\$ 6,789 <u>(1) (2)</u> 389.4759 <u>(1) (6)</u>	23,203,638	I	See note (4)
	02/16/2016		P			23,217,941	I	

Edgar Filing: REGENERON PHARMACEUTICALS INC - Form 4

Common Stock			14,303 <u>(1) (2)</u>		\$ 390.4695 <u>(1) (7)</u>				See note <u>(4)</u>
Common Stock	02/16/2016	P	33,131 <u>(1) (2)</u>	A	\$ 391.3591 <u>(1) (8)</u>	23,251,072	I		See note <u>(4)</u>
Common Stock	02/16/2016	P	14,692 <u>(1) (2)</u>	A	\$ 392.3656 <u>(1) (9)</u>	23,265,764	I		See note <u>(4)</u>
Common Stock	02/16/2016	P	7,301 <u>(1) (2)</u>	A	\$ 393.2723 <u>(1) (10)</u>	23,273,065	I		See note <u>(4)</u>
Common Stock	02/16/2016	P	600 ⁽¹⁾ <u>(2)</u>	A	\$ 393.95 <u>(1) (11)</u>	23,273,665	I		See note <u>(4)</u>
Common Stock	02/17/2016	P	1,507 <u>(1) (2)</u>	A	\$ 390.1449 <u>(1) (12)</u>	23,275,172	I		See note <u>(4)</u>
Common Stock	02/17/2016	P	3,681 <u>(1) (2)</u>	A	\$ 391.2307 <u>(1) (13)</u>	23,278,853	I		See note <u>(4)</u>
Common Stock	02/17/2016	P	27,088 <u>(1) (2)</u>	A	\$ 391.8482 <u>(1) (14)</u>	23,305,941	I		See note <u>(4)</u>
Common Stock	02/17/2016	P	6,730 <u>(1) (2)</u>	A	\$ 393.1577 <u>(1) (15)</u>	23,312,671	I		See note <u>(4)</u>
Common Stock	02/17/2016	P	12,988 <u>(1) (2)</u>	A	\$ 394.2403 <u>(1) (16)</u>	23,325,659	I		See note <u>(4)</u>
Common Stock	02/17/2016	P	13,288 <u>(1) (2)</u>	A	\$ 395.3203 <u>(1) (17)</u>	23,338,947	I		See note <u>(4)</u>
Common Stock	02/17/2016	P	11,018 <u>(1) (2)</u>	A	\$ 396.2026 <u>(1) (18)</u>	23,349,965	I		See note <u>(4)</u>
Common Stock	02/17/2016	P	3,400 <u>(1) (2)</u>	A	\$ 397.0707 <u>(1) (19)</u>	23,353,365	I		See note <u>(4)</u>
Common Stock	02/17/2016	P	300 ⁽¹⁾ <u>(2)</u>	A	\$ 398.38 <u>(1) (20)</u>	23,353,665	I		See note <u>(4)</u>

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not

SEC 1474
(9-02)

Edgar Filing: REGENERON PHARMACEUTICALS INC - Form 4

- (5) Purchase prices range from \$387.82 to \$388.73 per share, inclusive.
- (6) Purchase prices range from \$388.91 to \$389.90 per share, inclusive.
- (7) Purchase prices range from \$389.95 to \$390.93 per share, inclusive.
- (8) Purchase prices range from \$390.95 to \$391.93 per share, inclusive.
- (9) Purchase prices range from \$391.95 to \$392.94 per share, inclusive.
- (10) Purchase prices range from \$392.95 to \$393.87 per share, inclusive.
- (11) Purchase price was \$393.95 per share.
- (12) Purchase prices range from \$389.68 to \$390.52 per share, inclusive.
- (13) Purchase prices range from \$390.70 to \$391.69 per share, inclusive.
- (14) Purchase prices range from \$391.73 to \$392.71 per share, inclusive.
- (15) Purchase prices range from \$392.73 to \$393.66 per share, inclusive.
- (16) Purchase prices range from \$393.74 to \$394.72 per share, inclusive.
- (17) Purchase prices range from \$394.74 to \$395.73 per share, inclusive.
- (18) Purchase prices range from \$395.75 to \$396.74 per share, inclusive.
- (19) Purchase prices range from \$396.81 to \$397.68 per share, inclusive.
- (20) Purchase price was \$398.38 per share.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.